PhD in Biomedical Sciences and Biotechnology

 

Home –  PhD students –  Faculty –  Seminars

     

            1. Marisi G, Passardi A, Calistri D, Zoli W, Amadori D, Ulivi P. Discrepancies between VEGF −1154 G>A Polymorphism Analysis Performed in Peripheral Blood Samples and FFPE Tissue. Int. J. Mol. Sci. 2014 ; 15, 13333-13343
            2. Ulivi P, Scarpi E, Passardi A, Marisi G, Calistri D, Zoli W, Del Re M, Frassineti GL, Tassinari D, Tamberi S, Vertogen B, Amadori D. eNOS polymorphisms as predictors of efficacy of bevacizumab-based chemotherapy in metastatic colorectal cancer: data from a randomized clinical trial. J Transl Med. 2015; 13(1):258
            3. Casadei Gardini A, Marisi G, Scarpi E, Scartozzi M, Faloppi L, Silvestris N., et al. Effects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenib. Expert Opinion on Pharmacotherapy, 2015, 1:7
            4. Casadei Gardini A, Mariotti M, Lucchesi A, Pini S, Valgiusti M, Bravaccini S, Del Monte A, Burgio MA, Marisi G, Amadori D and Frassineti GL. Paraneoplastic lipase and amylase production in a patient with small-cell lung cancer: case report. BMC Cancer 2016;16(1):118
            5. Casadei Gardini A, Carloni S, Scarpi E,Maltoni P, Dorizzi RM, Passardi A, Frassineti GL, Cortesi P, Giannini MB, Marisi G, Amadori D, Lucchesi A. Prognostic role of serum concentrations of high-sensitivity C-reactive protein in patients with metastatic colorectal cancer: results from the ITACa trial . Oncotarget 2016, 7(9), 10193-10202. doi: 10.18632/oncotarget.7166.
            6. Casadei Gardini A, Scarpi E, Marisi G,Foschi GF, Donati G, Giampalma E, Faloppi L, Scartozzi M, Silvestris N, Bisulli M, Corbelli J, Gardini A, La Barba G, Veneroni L, Tamberi S, Cascinu S, Frassineti GL. Early onset of hypertension and serum electrolyte changes as potential predictive factors of activity in advanced HCC patients treated with sorafenib: results from a retrospective analysis of the HCC-AVR group. Oncotarget 2016, 7(12), 15243-15251 doi: 10.18632/oncotarget.7444
            7. Rodia MT, Ugolini G, Mattei G, Montroni I, Zattoni D, Ghignone F, Veronese G, Marisi G, Lauriola M, Strippoli P, Solmi R. Systematic large-scale meta-analysis identifies a panel of two mRNAs as blood biomarkers for colorectal cancer detection. Oncotarget. 2016, 5. doi:10.18632/oncotarget.8108.
            8. Casadei Gardini A, Marisi G, Faloppi L, Scarpi E, Foschi FG, Iavarone M, Lauletta G, Corbelli J,  Valgiusti M, Facchetti F, della Corte C, Neri LM, Tamberi S, Cascinu S, Scartozzi M, Amadori D, Nanni O, Tenti E,  Ulivi P and Frassineti GL. eNOS polymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: final results of the ePHAS study. Oncotarget. 2016, 7(19), 27988-27999
            9. Ulivi P, Marisi G, Passardi A. Relationship between hypoxia and response to antiangiogenic therapy in metastatic colorectal cancer. Oncotarget. 2016, 5. doi: 10.18632/oncotarget.8712.
            10. Alameen A.A.M, Simioni C., Martelli, A.M., Zauli G., Secchiero P., Ultimo S., McCubrey J.A., Marisi G., Ulivi P., Capitani S., and Neri L.M. Healthy CD4+ T lymphocytes are not affected by targeted therapies against the PI3K/AKT/mTOR pathway in T-cell acute lymphoblastic leukemia. Oncotarget. 2016;7(34):55690-55703. doi: 10.18632/oncotarget.10984
            11. Casadei Gardini A, Chiadini E, Faloppi L, Marisi G, Delmonte A, Scartozzi M, Loretelli C, Lucchesi A, Oboldi D, Dubini A, Frassineti GL, Ulivi P. Efficacy of sorafenib in BRAF-mutated non-small-cell lung cancer (NSCLC) and no response in synchronous BRAF wild type-hepatocellular carcinoma: a case report. BMC Cancer. 2016;16:429. doi: 10.1186/s12885-016-2463-2
            12. Casadei Gardini A, Scarpi E, Faloppi L, Scartozzi M, Silvestris N, Santini D, de Stefano G, Marisi G, Negri FV, Foschi FG, Valgiusti M, Ercolani G, Frassineti GL. Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib. Oncotarget. 2016;7(41):67142-67149. doi: 10.18632/oncotarget.11565
            13. Fornari F, Pollutri D, Patrizi C, La Bella T, Marinelli S, Casadei Gardini A, Marisi G, Baron Toaldo M, Baglioni M, Salvatore V, Callegari E, Baldassarre M, Galassi M, Giovannini C, Cescon M, Ravaioli M, Negrini M, Bolondi L, Gramantieri L. In Hepatocellular Carcinoma miR-221 Modulates Sorafenib Resistance through Inhibition of Caspase-3-Mediated Apoptosis. Clin Cancer Res. 2017;23(14):3953-3965. doi: 10.1158/1078-0432.CCR-16-1464.
            14. Casadei Gardini A, Foca F, Scartozzi M, Silvestris N, Tamburini E, Faloppi L, Brunetti O, Rudnas B, Pisconti S, Valgiusti M, Marisi G, Foschi FG, Ercolani G, Tassinari D, Cascinu S, Frassineti GL. Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: a retrospective study. Sci Rep. 2017;7:42499. doi: 10.1038/srep42499.
            15. Ultimo S, Simioni C, Martelli AM, Zauli G, Evangelisti C, Celeghini C, McCubrey JA, Marisi G, Ulivi P, Capitani S, Neri LM. PI3K isoform inhibition associated with anti Bcr-Abl drugs shows in vitro increased anti-leukemic activity in Philadelphia chromosome-positive B-acute lymphoblastic leukemia cell lines. Oncotarget. 2017;8(14):23213-23227. doi: 10.18632/oncotarget.15542.
            16. Marisi G, Scarpi E, Passardi A, Nanni O, Ragazzini A, Valgiusti M, Casadei Gardini A, Neri LM, Frassineti GL, Amadori D, Ulivi P. Circulating VEGF and eNOS variations as predictors of outcome in metastatic colorectal cancer patients receiving bevacizumab. Sci Rep. 2017;7(1):1293. doi: 10.1038/s41598-017-01420-0
            17. Ulivi P, Scarpi E, Chiadini E, Marisi G, Valgiusti M, Capelli L, Casadei Gardini A, Monti M, Ruscelli S, Frassineti GL, Calistri D, Amadori D, Passardi A. Right- vs. Left-Sided Metastatic Colorectal Cancer: Differences in Tumor Biology and Bevacizumab Efficacy. Int J Mol Sci. 2017;18(6). pii: E1240. doi: 10.3390/ijms18061240.
            18. Di Costanzo GG, Casadei Gardini A, Marisi G, Foschi FG, Scartozzi M, Granata R, Faloppi L, Cascinu S, Silvestris N, Brunetti O, Palmieri VO, Ercolani G, Tortora R. Validation of a Simple Scoring System to Predict Sorafenib Effectiveness in Patients with Hepatocellular Carcinoma. Target Oncol. 2017. doi: 10.1007/s11523-017-0522-5.